

Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide

Scott R. Solomon,¹ Michael T. Aubrey,² Xu Zhang,³ Katelin C. Jackson,¹ Lawrence E. Morris,¹ H. Kent Holland,¹ Melhem M. Solh,¹ and Asad Bashey¹

¹The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA; ²University of Colorado Cord Blood Bank & Clinimmune Laboratory, Aurora, CO; and ³School of Public Health, University of Texas, Houston, TX

Key Points

- HLA-DR, HLA-DQ or nonpermissive HLA-DP mm is associated with a survival and relapse benefit after haploidentical transplantation using PTCy.
- HLA mm at the A locus is associated with an increased risk of chronic GVHD.

HLA disparity is the major predictor of outcome following unrelated donor (UD) transplantation, where a single mismatch (mm) at the HLA-A, HLA-B, HLA-C, or HLA-DRB1 locus leads to increased mortality, and mismatching at multiple loci compounds this effect. In contrast, HLA disparity has not been shown to increase mortality in the context of haploidentical transplant using posttransplant cyclophosphamide (PTCy). To better define the consequences of loci-specific HLA mm, we analyzed 208 consecutive patients undergoing haploidentical transplantation for hematologic malignancy using PTCy at our institution (median age, 52 years [range, 19-75 years]; peripheral blood stem cell, 66%; reduced-intensity conditioning, 59%). Median follow-up was 65.4 months (range, 34.3-157.2 months). In univariate analysis, a single class II HLA mm at HLA-DR, HLA-DQ or a nonpermissive (np) HLA-DP mm had a protective effect on disease-free and overall survival (OS), primarily a result of reduced relapse risk. Furthermore, this survival effect was cumulative, so that patients with 3 class II mm (HLA-DR, HLA-DQ, and np HLA-DP) had the best OS. In multivariate analysis, HLA-DR mm and np HLA-DP mm were both independently associated with improved OS (hazard ratio [HR], 0.43; $P = .001$; and HR, 0.47; $P = .011$, respectively). In contrast, single or multiple mm at HLA-A, HLA-B, or HLA-C loci had no effect on acute graft-versus-host disease (GVHD), nonrelapse mortality (NRM), relapse, or survival, although the presence of an HLA-A mm was associated with increased chronic GVHD incidence. The association of class II mm with lower relapse occurred without a corresponding increase in NRM or acute or chronic GVHD. These findings will require validation in larger registry studies.

Introduction

Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative therapy for high-risk hematologic malignancies that are not curable by chemotherapy alone. Historically, the ability to offer HCT to all patients was limited by the availability of an HLA-matched related or unrelated donor (UD). With the administration of posttransplant cyclophosphamide (PTCy) as a strategy for graft-versus-host disease (GVHD) prophylaxis, haploidentical transplantation (haplo) has become an increasingly used donor source for patients lacking a suitably matched donor, leading to comparable transplant outcomes.^{1,2}

In the setting of UD transplantation utilizing conventional GVHD prophylaxis, HLA disparity is the major predictor of transplant outcome. In this context, a single allele- or antigen-level mismatch (mm) at the

Submitted 3 August 2020; accepted 21 September 2020; published online 27 October 2020. DOI 10.1182/bloodadvances.2020003110.

Send data sharing requests via e-mail to the corresponding author, Scott R. Solomon (ssolomon@bmtga.com).

The full-text version of this article contains a data supplement.
© 2020 by The American Society of Hematology

HLA-A, HLA-B, HLA-C, or HLA-DRB1 locus leads to increased mortality, and mismatching at multiple loci compounds this effect.³⁻⁵ Although mismatching at HLA-DQB1 and HLA-DPB1 has no apparent effect on survival in UD transplantation, the presence of a nonpermissive (np) mm according to the T-cell epitope (TCE) grouping⁶ results in excess nonrelapse and all-cause mortality.^{7,8} Therefore, optimal transplant outcome in UD transplantation is best achieved when donor and recipient are allele-level matched at HLA-A, HLA-B, HLA-C, and HLA-DR while avoiding an np HLA-DP mm.

In contrast to UD transplantation, there is no clear consensus regarding the consequences of HLA disparity in the context of haplo transplantation using PTCy, with most published studies showing no correlation of the number of HLA mm's with GVHD, relapse, all-cause mortality, or nonrelapse mortality (NRM).⁹⁻¹¹ In this study, we analyzed the contribution of mm at individual HLA loci on the incidence of acute and chronic GVHD, relapse/progression, NRM, and survival following haplo transplant with PTCy.

Methods

Patients and donors

Institutional review board approval was granted for this retrospective review of 208 consecutive patients who underwent a T-cell replete haplo-hematopoietic stem cell transplant for hematologic malignancy, transplanted between October 2005 and December 2016. Baseline characteristics were prospectively recorded in our institutional database, and events (relapse, death, cause of death, occurrence, and grading of acute and chronic GVHD) were entered into the database in real time. These data were retrospectively extracted from the database at the time of analysis.

Donors could be first- or second-degree relatives, including half-siblings, with 2 to 5 antigen or allelic mismatches at HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 in either the graft-versus-host (GVH) or host-versus-graft direction. Donors were required to share ≥ 1 matched allele at each HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 locus.

Histocompatibility testing

High-resolution HLA typing was performed on all donors and recipients at HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, and HLA-DPB1. HLA type was determined using Sanger sequencing of at least exons 2 and 3 of class I loci and at least exon 2 of class II loci (GenDx, Utrecht, The Netherlands). HLA-DPB1 TCE permissivity was determined using the algorithm described by Crivello et al.¹²

Panel reactive antibody was evaluated on single-antigen class I and II beads (One Lambda, Canoga Park, CA). Mean fluorescence intensity of donor-specific antibody >1000 was considered clinically relevant. All haploidentical donors were evaluated by flow cytometric crossmatch. Positive flow cytometric crossmatch in the presence of donor-specific antibody was considered a contraindication to transplant.

Transplant

Haplo transplants were performed following nonmyeloablative (NMA)² or myeloablative (MA)^{13,14} conditioning with PTCy as previously published. T-cell-replete bone marrow or peripheral blood stem cell (PBSC) grafts were administered on day 0 (CD34 dose capped at $5 \times 10^6/\text{kg}$), followed by PTCy on days +3 and +4. Tacrolimus and mycophenolate mofetil were started on day +5.

Mycophenolate mofetil was stopped without taper on day +35. In the absence of GVHD, tacrolimus was discontinued on day +180. Filgrastim was given from day +5 until neutrophil recovery.

Definitions and study end points

Primary outcomes analyzed were overall survival (OS), disease-free survival (DFS; survival without evidence of active malignancy after transplantation), relapse/progression of malignancy, and NRM. Acute GVHD was classified as clinically significant (grades 2-4) or severe (grades 3-4).¹⁵ Chronic GVHD was classified as mild, moderate, or severe by National Institutes of Health consensus criteria.¹⁶ Acute and chronic GVHD were evaluated and graded by a single practitioner within the program. NRM and relapse/progression were treated as competing risks.

Statistical methods

Cumulative incidences (CIs) of NRM, relapse/progression, acute GVHD, and chronic GVHD were computed to account for presence of competing risks.¹⁷ Probabilities of OS and DFS were estimated using the Kaplan-Meier method. We performed log-rank test and Gray's test to compare survival probabilities and CIs, respectively. We used the Cox proportional hazards models to examine effects of HLA loci mm on hazard functions for OS and DFS, as well as on cause-specific hazard functions for GVHD, relapse/progression, and NRM, while adjusting for significant patient-, disease-, and transplant-related factors. We considered the following variables in multivariate analysis (MVA): HLA-DR mm, np HLA-DP mm, age (<55 years vs ≥ 55 years), recipient sex, diagnosis (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], or other), stem cell source (bone marrow or PBSC), intensity (MA vs NMA), Disease Risk Index (DRI) (high/very high, low/intermediate), HCT-specific comorbidity index (0-2 vs ≥ 3), donor age (<40 years vs ≥ 40 years), donor sex, cytomegalovirus (CMV) (D- R+, other), ABO compatibility (compatible, minor incompatible, or major incompatible), donor relationship (child, sibling, or parent), and year of transplantation (2005-2010, 2011-2013, and 2014-2016). The forward stepwise selection algorithm was implemented for each end point, and variables were selected by the 5% significance criterion. The final Cox models for OS, DFS, NRM, and relapse/progression were constructed by including all the variables significant for ≥ 1 end point. The proportional hazard assumption for a covariate Z was assessed by creating and testing the time-dependent variable $Z \times \log(t)$. All covariates in the final Cox models passed the tests of proportionality. Statistical analysis was performed using the software SAS (version 9.4, the SAS Institute, Cary, NC) and the R package "cmprsk" (www.r-project.org).

Results

Patient, disease, and transplant characteristics

Baseline patient, disease, and transplant characteristics are shown in Table 1. Median (range) recipient age was 52 (19-75) years, and 54% were male. HCT-specific comorbidity index was ≥ 3 in 46%. Patients were most frequently transplanted for AML (34%), non-Hodgkin lymphoma/Hodgkin disease/chronic lymphocytic leukemia (25%), myelodysplastic/myeloproliferative neoplasms/chronic myeloid leukemia (20%), and ALL (17%). DRI was low, intermediate, and high/very high in 14%, 48% and 37% respectively. Seventy-seven percent were CMV seropositive; CMV-seronegative donor/CMV-seropositive recipient combination occurred in 27% of

Table 1. Baseline characteristics (N = 208)

	Number of patients
Recipient age, median (min, max), y	52 (19, 75)
Donor age, median (min, max), y	38 (15, 73)
Male	113 (54)
Race	
White	123 (59)
Black	80 (39)
Asian	5 (2)
Recipient CMV status	
Positive	161 (77)
Negative	47 (23)
Disease type	
AML	71 (34)
NHL/HD/CLL	51 (25)
MDS/MPN/CML	42 (20)
ALL	36 (17)
MM	5 (3)
AL	3 (1)
DRI	
Low	30 (14)
Intermediate	100 (48)
High	68 (33)
Very high	9 (4)
N/A	1 (1)
HCT-specific comorbidity index	
0-2	113 (54)
≥3	95 (46)
Stem cell source	
PBSC	137 (66)
BM	71 (34)
Conditioning intensity	
NMA	122 (59)
MA	86 (41)
Donor-recipient relationship	
Child	99 (47)
Sibling/half sibling	79 (38)
Parent	29 (14)
Niece/nephew	1 (1)
Year of transplant	
2005-2010	49 (24)
2011-2013	63 (30)
2014-2016	96 (46)
Number of survivors	105
Survivor follow-up, median (min, max), mo	65.4 (34.3, 157.2)

Values are presented as the number (percentage) of patients unless otherwise indicated. AL, acute leukemia unspecified; BM, bone marrow; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; HD, Hodgkin disease; MDS/MPN, myelodysplastic/myeloproliferative neoplasms; MM, multiple myeloma; N/A, not available; NHL, non-Hodgkin lymphoma.

Table 2. Donor-recipient HLA disparity (N = 208)

	Number of patients
x/12 mm GVH (HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, HLA-DP)	
1	4 (2)
2	8 (4)
3	17 (8)
4	38 (18)
5	76 (37)
6	65 (31)
x/10 mm GVH (HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ)	
1	5 (2)
2	16 (8)
3	28 (13)
4	56 (27)
5	103 (50)
x/8 mm GVH (HLA-A, HLA-B, HLA-C, HLA-DR)	
1	13 (6)
2	20 (10)
3	53 (25)
4	122 (59)
Presence of HLA-A mm GVH	164 (79)
Presence of HLA-B mm GVH	186 (89)
Presence of HLA-C mm GVH	174 (84)
Presence of HLA-DR mm GVH	176 (85)
Presence of HLA-DQ mm GVH	160 (77)
Presence of HLA-DP mm (TCE)	
Nonpermissive mm	48 (23)
Permissive mm	115 (55)
HLA-DP match	45 (22)

Values are presented as the number (percentage) of patients.

transplants. The donor was a child, sibling/half sibling, or parent in 47%, 38%, and 14%, respectively. PBSCs were used as the stem cell source in 66% of patients, and conditioning intensity was reduced in 59%.

Donor-recipient HLA disparity

A summary of donor-recipient HLA disparity, total and per loci, are shown in Table 2. The total number of HLA mm (HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1) in the GVH direction between donor and recipient was 5, 4, and ≤3 in 50%, 27%, and 23%, respectively. Individual loci mm in the GVH direction for HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-DQ was seen in 79%, 89%, 84%, 85%, and 77%, respectively. HLA-DP was matched, permissive mm, and nonpermissive (np) mm in 22%, 55%, and 23%, respectively.

Transplant outcomes for the entire cohort and impact of overall HLA matching

After a median (range) follow-up for surviving patients of 65.4 (34.3-157.2) months, 5-year OS, DFS, relapse/progression, and NRM for




Figure 1. Effect of cumulative HLA allele mismatch on transplant outcomes. OS (A), DFS (B), relapse/progression (C), NRM (D), grade II-IV acute GVHD (E), and moderate-to-severe chronic GVHD (F), according to the total number of HLA mismatches (5-6 vs 1-4 out of 12).

all patients were 53%, 46%, 37%, and 17%, respectively. The CI of grade II to IV and grade III to IV acute GVHD at 6 months was 44% and 17%, respectively. The CI of all-grade and moderate-to-severe chronic GVHD at 3 years was 34% and 25%, respectively. Graft failure occurred in 5 patients (2.4%), all of whom were successfully regrafted with a second haplo transplant.

To analyze the effect of overall HLA disparity, we compared outcomes of transplants where donor and recipient had 5 or 6 (out

of 12) antigen or allelic mismatches at HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, or HLA-DP in the GVH direction ($n = 141$) vs those with 1 to 4 out of 12 mismatches ($n = 67$). There were no significant differences in OS, DFS, NRM, or acute GVHD between the groups. However, patients with less mismatch (1-4 vs 5-6) had a statistically higher incidence of relapse and a trend toward a lower incidence of chronic GVHD (Figure 1). A similar pattern was seen when the analysis was restricted to 10 loci (HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-DQ; supplemental Figure 1).




Figure 2. Effect of loci-specific HLA mismatch on OS. OS according to the presence/absence of a loci-specific HLA mismatch at HLA-A (A), HLA-B (B), HLA-C (C), HLA-DR (D), HLA-DQ (E), HLA-DP (F), or the presence/absence of an np HLA-DP mismatch (G).

Table 3. Cox analysis of OS, DFS, relapse, and NRM

Variable	Effect	OS		DFS		Relapse		NRM	
		HR	P	HR	P	HR	P	HR	P
HLA-DR mm GVH	Yes vs no	0.43	.001	0.47	.002	0.51	.023	0.39	.031
HLA-DP np mm	Yes vs no	0.47	.011	0.54	.019	0.44	.015	0.78	.555
CMV	D– R+ vs other	1.57	.043	1.51	.049	1.34	.259	1.83	.083
Patient age, y	≥55 vs <55	1.92	.002	1.76	.005	1.62	.052	2.04	.040
Race	Black vs White	0.60	.026	0.60	.015	0.63	.070	0.51	.075
DRI	High/very high vs low/intermediate	2.17	<.001	2.04	<.001	2.39	<.001	1.51	.234
Year of transplantation	2011-2013 vs 2005-2010	0.97	.901	0.90	.700	0.60	.118	2.02	.147
	2014-2016 vs 2005-2010	0.56	.031	0.70	.151	0.59	.075	1.04	.934

We considered the following variables in MVA: HLA-DR mm, HLA-DP np mm, age (<55 years vs ≥55 years), recipient sex, diagnosis (AML, ALL, or other), stem cell source (bone marrow vs PBSC), intensity (MA vs NMA), DRI (high/very high vs low/intermediate), HCT-specific comorbidity index (0-2 vs ≥3), donor age (<40 years vs ≥40 years), donor sex, CMV (D– R+ vs other), ABO compatibility (compatible, minor incompatible, or major incompatible), donor relationship (child, sibling, or parent), and year of transplantation (2005-2010, 2011-2013, or 2014-2016). The forward stepwise selection algorithm was implemented for each end point, and variables were selected by the 5% significance criterion. The final Cox models for OS, DFS, NRM, and relapse/progression were constructed by including all the variables significant for ≥1 end point.

Survival, relapse/progression, and NRM according to individual HLA loci disparity

In univariate analysis, there was no effect of class I mm in the GVH direction at HLA-A, HLA-B, or HLA-C loci on OS (Figure 2A-C). Similarly, mm at HLA-A, HLA-B, or HLA-C loci had no effect on DFS or CI of relapse/progression or NRM (data not shown). In contrast, class II mm GVH had a significant impact on OS. Transplants where either an HLA-DR or HLA-DQ mm was present were associated with a significant improvement in OS ($P = .002$ and $P = .014$, respectively; Figure 2D-E). Estimated 5-year OS in patients where either HLA-DR or HLA-DQ was mismatched vs matched was 57% vs 29% and 57% vs 39%, respectively. Unlike HLA-DR and HLA-DQ, mm at HLA-DP had no effect on OS (Figure 2F), with an estimated 5-year OS of 52% vs 56%. However, if restricted only to an np HLA-DP mm, there was a significant OS benefit to having an np HLA-DP mm, with estimated 5-year OS of 68% vs 49% ($P = .029$; Figure 2G).

The impact of class II mm was further analyzed in a Cox MVA while adjusting for other significant covariates such as age (≥55 years vs <55 years), race (black vs white), DRI (high/very high vs low/intermediate), CMV (D– R+ vs other), and year of transplant (Table 3). As HLA-DR and HLA-DQ were strongly correlated, given their known genetic linkage disequilibrium, only HLA-DR was considered. In this analysis, the presence of an HLA-DR mm (hazard ratio [HR], 0.43; $P = .001$) or HLA-DP mm (HR, 0.47; $P = .011$) was independently associated with improved OS. A similar association was also noted with DFS (HR, 0.47; $P = .002$; and HR, 0.54; $P = .019$ respectively; Table 3).

The presence of an HLA-DR, HLA-DQ or np HLA-DP mm was also associated with a reduction of relapse/progression. In univariate analysis, the 5-year CI of relapse/progression was lower in transplants associated with an HLA-DR mm GVH (34% vs 50%, $P = .05$). Likewise, HLA-DQ and np HLA-DP mm were also associated with lower 5-year relapse risk (34% vs 44%, $P = .16$; and 25% vs 40%, $P = .07$, respectively). In Cox MVA, significant relapse reduction was noted with either an HLA-DR mm (HR, 0.51; $P = .023$) or an np HLA-DP mm (HR, 0.44; $P = .015$), while adjusting for other significant covariates (Table 3). HLA-DR mm also demonstrated a protective effect against NRM (HR, 0.39; $P = .031$), whereas np HLA-DP mm had no significant impact on NRM

(Table 3). Class I mm at HLA-A, HLA-B, or HLA-C had no impact on either relapse/progression or NRM.

We further analyzed the cumulative effect of the number of class II mm's (HLA-DR, HLA-DQ, and np HLA-DP). Figure 3 shows the relative impact on OS, DFS, relapse, and NRM of having 0 or 1 vs 2 vs 3 class II mm's. Estimated 5-year OS was improved with an increasing number of class II mm's (estimated to be 32%, 55% and 76%, respectively). Similarly, 5-year DFS was also improved with increasing class II mm's (28%, 49%, and 62%, respectively). Risk of relapse/progression at 5 years posttransplant was highest in patients with 0 or 1 class II mm's (50% vs 33% and 31% in patients with 2 and 3 mm's, respectively). CI of NRM at 5 years posttransplant was lowest in patients with 3 class II mm's (7% vs 18% and 22% in patients with 2 and 0 or 1 mm, respectively). There was no association of the cumulative number of class I mm's (HLA-A, HLA-B, or HLA-C) with OS, DFS, NRM, or relapse/progression.

GVHD according to HLA loci disparity

In univariate analysis, there was no significant effect of mm at any class I (HLA-A, HLA-B, or HLA-C) or class II (HLA-DR, HLA-DQ, or np HLA-DP) loci on the CI of either grade II-IV or III-IV acute GVHD. Supplemental Figure 2 shows the CI of grade II to IV acute GVHD according to the presence of mm's at each individual locus.

Figure 4 shows the CI of chronic GVHD according to the presence of mm's at each individual locus. Among class I HLA loci, only the presence of an mm at the HLA-A locus was associated with increased risk of chronic GVHD (39 vs 19%, $P = .01$). An HLA-A mm was also associated with an increased incidence of moderate-to-severe chronic GVHD (29% vs 14%, $P = .043$). There was no association of class II HLA mm at any locus and the CI of chronic GVHD. The impact of HLA-A mm was further analyzed in a Cox MVA while adjusting for other significant covariates such as race (black vs white). In MVA, the association of HLA-A mm with chronic GVHD remained significant (HR, 2.17; $P = .041$).

Discussion

In this large, single-center, retrospective analysis with mature follow-up (median of 5 years), we demonstrate the protective effect of class II HLA mm on survival after haplo transplantation utilizing




Figure 3. Transplant outcomes according to the total number of class II HLA mismatches. OS (A), DFS (B), relapse/progression (C), and NRM (D) according to the number of class II HLA mismatches

PTCy. The presence of an mm at HLA-DR, HLA-DQ or the presence of an np mm at HLA-DP are each associated with a statistically significant improvement in OS. Furthermore, this effect appears to be cumulative, so that patients with 3 class II mm's (HLA-DR, HLA-DQ, and np HLA-DP) have the best OS. The survival advantage in patients with an HLA class II mm is primarily the result of reduced relapse risk. Remarkably, this association of class II mm with lower relapse occurs without a corresponding increase in NRM. In fact, the presence of an HLA-DR mm was associated with lower NRM in this analysis. In contrast to the significant impact of class II HLA mm's, there is no apparent effect of class I HLA mm's at the HLA-A, HLA-B, or HLA-C locus on survival or relapse incidence, although the presence of an HLA-A mm is associated with an increased risk of chronic GVHD.

Outside of the context of haplo transplant with PTCy, HLA disparity has generally been associated with inferior survival. For example, in UD transplantation using standard GVHD prophylaxis, the presence of a single-allele- or antigen-level mm at the HLA-A, HLA-B, HLA-C, or HLA-DRB1 locus results in excess mortality, and mismatching at multiple loci compounds this effect.³⁻⁵ Although no such association has been shown with HLA-DQ or HLA-DP mm, the presence of an HLA-DP np mm according to the TCE algorithm results in higher nonrelapse and all-cause mortality.^{7,8} In the context of single or double umbilical cord blood (UCB) transplantation, the

consequences of HLA disparity are much less clear, with conflicting reports showing that a higher degree of HLA disparity is associated with inferior,¹⁸⁻²¹ neutral,²² or superior²³⁻²⁶ transplant outcomes.

Our results are in concordance with other published studies⁹⁻¹¹ showing that survival after haplo transplant using PTCy does not appear to be significantly impacted by the total number of HLA mm's on the unshared haplotype when specific HLA loci are not taken into account. However, the consequences of an individual HLA mm at selective loci has been less well studied and remains an open area of investigation. For example, an analysis by the Johns Hopkins group demonstrated that the presence of an antigenic HLA-DR mm was associated with decreased relapse and improved DFS following haplo transplant using PTCy. This study analyzed a uniformly treated patient population receiving NMA conditioning and bone marrow exclusively as the stem cell source.⁹ In contrast to those results, a European registry analysis by Lorentino et al, with more heterogenous conditioning regimens and the use of peripheral blood in addition to marrow as a stem cell source, failed to show an effect of HLA-DR mm on relapse or survival, but it did show an association with increased grade 2 to 4 acute GVHD.¹⁰

The results of our analysis strongly suggest that selective mm's at class II loci (HLA-DR, HLA-DQ, and np HLA-DP mm) are associated with reduced relapse and improved survival in the context of haplo transplant using PTCy. On the contrary, class I mm's (HLA-A,




Figure 4. HLA loci-specific chronic GVHD incidence. Cumulative incidence of chronic GVHD according to presence/absence of an HLA mismatch at HLA-A (A), HLA-B (B), HLA-C (C), HLA-DR (D), HLA-DQ (E), and nonpermissive HLA-DP (F).

HLA-B, or HLA-C) had no impact on relapse or survival. Of note, both HLA-DR and HLA-DP mm's have been associated with reduced relapse risk in the context of UD^{7,8,27} and UCB^{18,25,28} transplantation, and HLA-DR mm has been associated with improved survival in the setting of UCB transplant in one study.²⁵ However, in the UD setting using conventional GVHD prophylaxis, HLA-DR mm and np HLA-DP mm are also associated with higher risks of GVHD and NRM, negating any beneficial effect on transplant outcome.^{7,29-31} We believe that the absence of compensatory increase in NRM in haplo transplant is likely the result of PTCy-based GVHD prophylaxis.

We hypothesize that the relapse/survival benefits of class II HLA mismatch, without associated increases in GVHD/NRM, are likely based on several important immunological principles: (1) the robust alloresponse that occurs when crossing HLA barriers, (2) the unique mechanisms of PTCy-mediated allodepletion, and (3) the preferential expression of class II HLA antigens on hematopoietic cells. Alloreactive T cells against foreign HLA are found naturally in high frequency in the normal T-cell repertoire.³² Such T cells are similarly present in the naive and memory T-cell compartment.³³ PTCy efficiently depletes rapidly dividing alloreactive memory T cells

due to their rapid activation kinetics and sensitivity of activated T cells to Cy-induced elimination, resulting in partial abrogation of the T-cell response to mismatched HLA.³⁴ In contrast, it has been proposed that residual alloreactive T cells from the naive T-cell compartment, having slower kinetics of activation, can preferentially survive the effects of PTCy and result in preservation of at least some anti-malignancy activity with acceptable GVHD.³⁴ Unlike HLA class I molecules, which are expressed on a wide variety of nucleated cells, HLA class II molecules are preferentially expressed on cells of hematopoietic origin. Therefore, it is plausible that CD4 T cells targeting class II antigens on hematopoietic cancer cells, partially surviving PTCy-induced allodepletion, may be the main drivers of the selective graft-versus-malignancy responses seen in this context, an idea which is supported by significant preclinical data.³⁵⁻³⁸

The finding of lower NRM associated with the presence of an HLA-DR GVH mm was an unexpected observation in this analysis. As HLA-DR disparity is a major contributor of the strength of the alloresponse in the *in vitro* mixed lymphocyte response,³⁹ we hypothesize that HLA-DR disparity may accelerate the kinetics of T-cell activation *in vivo* and thus improve the efficiency of cyclophosphamide-induced allodepletion and/or regulatory T-cell generation,^{40,41} which may result in less infectious or GVHD-related mortality. In our analysis, 5-year NRM was substantially lower in HLA-DR GVH mm patients (16% vs 27%). Furthermore, GVHD-related death appeared to be higher following HLA-DR GVH matched patients, with 4 of the 8 (50%) nonrelapse deaths occurring in the context of active treatment of NIH-defined severe chronic GVHD compared with 1 of 28 (4%) nonrelapse deaths in the HLA-DR GVH mm group. In contrast to HLA-DRB1 mm, there was no NRM advantage seen with either HLA-DQB1 or HLA-npDPB1 mm, a finding that may relate to the significantly lower expression of these antigens on the surface of antigen-presenting cells compared with HLA-DRB1.⁴²⁻⁴⁴ This observation, although provocative, clearly needs to be validated in a larger study population.

In the context of UD transplantation, HLA disparity at HLA-A, HLA-B, HLA-C, or HLA-DR is associated with a significant increase in the incidence and severity of acute GVHD, and this effect was compounded in the setting of multiple HLA mismatches.^{4,45} In contrast, our data show no correlation between HLA disparity at any loci and the incidence of acute GVHD following PTCy-based haplo transplantation. With regard to chronic GVHD, however, we show that the presence of an HLA-A mm in the GVH direction is associated with an increased risk of all-grade and moderate-to-severe chronic GVHD. This association, although not previously reported in the setting of PTCy-based haplo transplant, is supported by comparable data in the context of UD transplantation.^{4,45,46} Furthermore, the same association of HLA-A mm with chronic GVHD has also been seen in the context of UCB transplantation, although limited to UCB transplants that were mismatched at 3 or 4 other loci.¹⁸

We believe that the association of class II mm with improved OS may have significant implications for donor selection in the context of haplo transplant using PTCy. As most patients have >1 available potential haplo donor options, choosing donors that maximize class II mm (ie, avoiding HLA-DR and HLA-DQ matching in the GVH direction and prioritizing an np HLA-DP mm) may improve overall transplant outcome. Furthermore, with the increasing use of PTCy-based GVHD prophylaxis for mismatched UD transplantation,⁴⁷⁻⁴⁹ it will be important to evaluate the impact of class II mismatching in this setting as well.

In conclusion, our results confirm historical data showing that the total number of HLA mismatches, irrespective of HLA loci, does not impact mortality risk in the context of PTCy-based haplo transplantation. Conversely, we show the importance of certain loci-specific HLA mismatches in transplant outcome. We report that class II mm's (HLA-DR mm, HLA-DQ mm, or np HLA-DP mm) are associated with improved survival after haplo transplant utilizing PTCy, a product of lower relapse without a corresponding increase in NRM. Furthermore, we show that HLA-A mismatch is associated with a higher risk of chronic GVHD, without any corresponding effects on survival or relapse. This study does have several important limitations. First, although this represents a fairly robust single-center study, it does not have the power of a large registry study for detecting small differences in HLA-locus-specific outcomes. Second, our population is relatively heterogenous based on disease, stem cell source, and conditioning intensity. Despite these limitations, this study represents the most comprehensive analysis of HLA disparity in the context of PTCy-based haploidentical PBSC transplantation to date. These findings will require validation in larger registry studies.

Acknowledgment

The authors are grateful to all the clinicians and support staff at the Blood and Marrow Transplant Program at Northside Hospital Cancer Institute for their excellent care of our transplant patients.

Authorship

Contribution: S.R.S. designed the research; S.R.S., M.M.S., L.E.M., H.K.H, and A.B. treated patients; M.T.A. and K.C.J. collected the data; S.R.S. and X.Z. analyzed and interpreted data; X.Z. performed the statistical analysis; S.R.S. wrote the manuscript; and all authors revised and approved the final version of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profile: S.R.S., 0000-0003-2061-8126.

Correspondence: Scott R. Solomon, Northside Hospital Cancer Institute, 5670 Peachtree Dunwoody Rd NE, Suite 1000, 10th Floor, Atlanta, GA 30342; e-mail: ssolomon@bmtga.com.

References

1. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. *Biol Blood Marrow Transplant*. 2008;14(6):641-650.
2. Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. *J Clin Oncol*. 2013;31(10):1310-1316.

3. Petersdorf EW, Anasetti C, Martin PJ, et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. *Blood*. 2004;104(9):2976-2980.
4. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. *Blood*. 2004;104(7):1923-1930.
5. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. *Blood*. 2007;110(13):4576-4583.
6. Zino E, Frumento G, Markt S, et al. A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. *Blood*. 2004;103(4):1417-1424.
7. Fleischhauer K, Shaw BE, Gooley T, et al; International Histocompatibility Working Group in Hematopoietic Cell Transplantation. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. *Lancet Oncol*. 2012;13(4):366-374.
8. Pidala J, Lee SJ, Ahn KW, et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. *Blood*. 2014;124(16):2596-2606.
9. Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. *Biol Blood Marrow Transplant*. 2010;16(4):482-489.
10. Lorentino F, Labopin M, Fleischhauer K, et al. The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. *Blood Adv*. 2017;1(11):669-680.
11. Raiola AM, Risitano A, Sacchi N, et al. Impact of HLA disparity in haploidentical bone marrow transplantation followed by high-dose cyclophosphamide. *Biol Blood Marrow Transplant*. 2018;24(1):119-126.
12. Crivello P, Zito L, Sizzano F, et al. The impact of amino acid variability on alloreactivity defines a functional distance predictive of permissive HLA-DPB1 mismatches in hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2015;21(2):233-241.
13. Solomon SR, Sizemore CA, Sanacore M, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. *Biol Blood Marrow Transplant*. 2012;18(12):1859-1866.
14. Solomon SR, Sizemore CA, Sanacore M, et al. Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. *Biol Blood Marrow Transplant*. 2015;21(7):1299-1307.
15. Gratwohl A, Hermans J, Apperley J, et al; Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. *Blood*. 1995;86(2):813-818.
16. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. *Biol Blood Marrow Transplant*. 2005;11(12):945-956.
17. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. *Bone Marrow Transplant*. 2001;28(11):1001-1011.
18. Eapen M, Klein JP, Sanz GF, et al; Center for International Blood and Marrow Transplant Research. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. *Lancet Oncol*. 2011;12(13):1214-1221.
19. Eapen M, Klein JP, Ruggeri A, et al; Center for International Blood and Marrow Transplant Research, Netcord, Eurocord, and the European Group for Blood and Marrow Transplantation. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. *Blood*. 2014;123(1):133-140.
20. Oran B, Cao K, Saliba RM, et al. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. *Haematologica*. 2015;100(10):1361-1370.
21. Yokoyama H, Morishima Y, Fuji S, et al; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Impact of HLA allele mismatch at HLA-A, -B, -C, and -DRB1 in single cord blood transplantation. *Biol Blood Marrow Transplant*. 2020;26(3):519-528.
22. Yanada M, Konuma T, Kuwatsuka Y, et al. Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience. *Bone Marrow Transplant*. 2019;54(11):1789-1798.
23. Sanz J, Jaramillo FJ, Planelles D, et al. Impact on outcomes of human leukocyte antigen matching by allele-level typing in adults with acute myeloid leukemia undergoing umbilical cord blood transplantation. *Biol Blood Marrow Transplant*. 2014;20(1):106-110.
24. Wagner JE Jr., Eapen M, Carter S, et al; Blood and Marrow Transplant Clinical Trials Network. One-unit versus two-unit cord-blood transplantation for hematologic cancers. *N Engl J Med*. 2014;371(18):1685-1694.
25. Konuma T, Kato S, Ishii H, et al. HLA-DRB1 mismatch is associated with a decreased relapse in adult acute myeloid leukemia after single-unit myeloablative cord blood transplantation. *Ann Hematol*. 2015;94(7):1233-1235.
26. Brunstein CG, Petersdorf EW, DeFor TE, et al. Impact of allele-level HLA mismatch on outcomes in recipients of double umbilical cord blood transplantation. *Biol Blood Marrow Transplant*. 2016;22(3):487-492.
27. Atsuta Y, Kato S, Morishima Y, et al; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Comparison of HLA allele mismatch and antigen mismatch in unrelated bone marrow transplantation in patients with leukemia. *Biol Blood Marrow Transplant*. 2019;25(3):436-442.
28. Yabe T, Azuma F, Kashiwase K, et al; Japanese Cord Blood Transplantation Histocompatibility Research Group. HLA-DPB1 mismatch induces a graft-versus-leukemia effect without severe acute GVHD after single-unit umbilical cord blood transplantation. *Leukemia*. 2018;32(1):168-175.
29. Gajewski J, Gjertson D, Cecka M, et al. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. *Biol Blood Marrow Transplant*. 1997;3(2):76-82.

30. Inamoto Y, Kuwatsuka Y, Oba T, et al. Serologically HLA-DR-mismatched unrelated donors might provide a valuable alternative in allogeneic transplantation: experience from a single Japanese institution. *Int J Hematol*. 2007;85(2):163-169.
31. Przepiorka D, Saliba R, Cleary K, et al. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. *Biol Blood Marrow Transplant*. 2000;6(22A):190-197.
32. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. *J Immunol*. 2001;166(2):973-981.
33. Macedo C, Orkis EA, Popescu I, et al. Contribution of naïve and memory T-cell populations to the human alloimmune response. *Am J Transplant*. 2009;9(9):2057-2066.
34. Roberto A, Castagna L, Zanon V, et al. Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. *Blood*. 2015;125(18):2855-2864.
35. Rutten CE, van Luxemburg-Heijs SA, Halkes CJ, et al. Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease. *Biol Blood Marrow Transplant*. 2013;19(1):40-48.
36. Stevanović S, Nijmeijer BA, van Schie ML, et al. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia. *Biol Blood Marrow Transplant*. 2013;19(6):867-875.
37. Stevanović S, van Schie ML, Griffioen M, Falkenburg JH. HLA-class II disparity is necessary for effective T cell mediated Graft-versus-Leukemia effects in NOD/scid mice engrafted with human acute lymphoblastic leukemia. *Leukemia*. 2013;27(4):985-987.
38. Zheng H, Matte-Martone C, Li H, et al. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. *Blood*. 2008;111(4):2476-2484.
39. Smith RA, Belcher R. Disparity in HLA-DR typing and mixed lymphocyte culture reactivity. *Ann Clin Lab Sci*. 1987;17(5):318-323.
40. Luznik L, O'Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. *Semin Oncol*. 2012;39(6):683-693.
41. Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. *J Clin Invest*. 2019;129(6):2357-2373.
42. Nuñez G, Ball EJ, Myers LK, Stastny P. Allostimulating cells in man. Quantitative variation in the expression of HLA-DR and HLA-DQ molecules influences T-cell activation. *Immunogenetics*. 1985;22(1):85-91.
43. Fernández-Viña MA, Klein JP, Haagenson M, et al. Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. *Blood*. 2013;121(22):4603-4610.
44. Yamamoto F, Suzuki S, Mizutani A, et al. Capturing differential allele-level expression and genotypes of all classical HLA loci and haplotypes by a new capture RNA-seq method. *Front Immunol*. 2020;11:941.
45. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. *Blood*. 2002;99(11):4200-4206.
46. Tie R, Zhang T, Yang B, et al. Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysis. *Oncotarget*. 2017;8(16):27645-27660.
47. Gaballa S, Ge I, El Fakih R, et al. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. *Cancer*. 2016;122(21):3316-3326.
48. Mehta RS, Saliba RM, Chen J, et al. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. *Br J Haematol*. 2016;173(3):444-455.
49. Kasamon YL, Ambinder RF, Fuchs EJ, et al. Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. *Blood Adv*. 2017;1(4):288-292.